Chris Schott
Stock Analyst at JP Morgan
(3.23)
# 1,008
Out of 4,667 analysts
122
Total ratings
48.57%
Success rate
1.16%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $167.76 | +19.22% | 2 | Nov 13, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $100 → $105 | $88.63 | +18.47% | 3 | Nov 7, 2024 | |
| BIIB Biogen | Maintains: Neutral | $220 → $210 | $156.00 | +34.62% | 3 | Nov 4, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,200 → $1,150 | $742.09 | +54.97% | 5 | Oct 24, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Neutral | $16 → $18 | $17.05 | +5.57% | 15 | Oct 21, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $418.61 | +37.36% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $175.30 | +31.20% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $1,050 → $1,100 | $753.41 | +46.00% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $14.73 | +35.78% | 2 | Sep 6, 2024 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Neutral | $9 | $8.40 | +7.14% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $27.15 | +51.01% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $26.22 | +60.18% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $287.87 | -6.21% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.85 | +36.82% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $97.44 | +28.28% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $13.13 | +6.63% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.10 | +900.00% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $13.44 | +48.81% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.19 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $58.16 | +34.12% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $6.43 | +14,674.49% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.34 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $17.03 | +193.60% | 3 | Nov 2, 2018 |
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $167.76
Upside: +19.22%
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $100 → $105
Current: $88.63
Upside: +18.47%
Biogen
Nov 4, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $156.00
Upside: +34.62%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Overweight
Price Target: $1,200 → $1,150
Current: $742.09
Upside: +54.97%
Teva Pharmaceutical
Oct 21, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $17.05
Upside: +5.57%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $418.61
Upside: +37.36%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $175.30
Upside: +31.20%
Eli Lilly
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $753.41
Upside: +46.00%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $14.73
Upside: +35.78%
Amneal Pharmaceuticals
Sep 6, 2024
Upgrades: Neutral
Price Target: $9
Current: $8.40
Upside: +7.14%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $27.15
Upside: +51.01%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $26.22
Upside: +60.18%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $287.87
Upside: -6.21%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.85
Upside: +36.82%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $97.44
Upside: +28.28%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $13.13
Upside: +6.63%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.10
Upside: +900.00%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $13.44
Upside: +48.81%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.19
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $58.16
Upside: +34.12%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $6.43
Upside: +14,674.49%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.34
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $17.03
Upside: +193.60%